Nhytideta 0,075 mg/0,020 mg tabletten

Land: Holland

Tungumál: hollenska

Heimild: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

Kauptu það núna

Download Vara einkenni (SPC)
28-06-2023

Virkt innihaldsefni:

ETHINYLESTRADIOL 0,02 mg/stuk ; GESTODEEN 0,075 mg/stuk

Fáanlegur frá:

Laboratorios Leon Farma, S.A. C/La Vallina s/n, Pol. Ind. 24008 NAVATEJERA (SPANJE)

ATC númer:

G03AA10

INN (Alþjóðlegt nafn):

ETHINYLESTRADIOL 0,02 mg/stuk ; GESTODEEN 0,075 mg/stuk

Lyfjaform:

Tablet

Samsetning:

CELLULOSE, MICROKRISTALLIJN (E 460(i)) ; LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b) ; POLACRILINE KALIUM ; POVIDON K 30 (E 1201), CELLULOSE, MICROKRISTALLIJN (E 460) ; LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b) ; POLACRILINE KALIUM ; POVIDON K 30 (E 1201),

Stjórnsýsluleið:

Oraal gebruik

Lækningarsvæði:

Gestodene And Ethinylestradiol

Vörulýsing:

Hulpstoffen: CELLULOSE, MICROKRISTALLIJN (E 460); LACTOSE 1-WATER; MAGNESIUMSTEARAAT (E 470b); POLACRILINE KALIUM; POVIDON K 30 (E 1201);

Leyfisdagur:

1900-01-01

Upplýsingar fylgiseðill

                                1
B. PACKAGE LEAFLET
LF-GSTDEE-NL-NL.H.2961.001.IA.019&II.013-D0
2
PACKAGE LEAFLET: INFORMATION FOR THE USER NHYTIDETA 0,075 MG/ 0,020 MG TABLETTEN
Gestodene / Ethinylestradiol
IMPORTANT THINGS TO KNOW ABOUT COMBINED HORMONAL CONTRACEPTIVES
(CHCS):
•
They are one of the most reliable reversible methods of contraception
if used correctly
•
They slightly increase the risk of having a blood clot in the veins
and arteries, especially in
the first year or when restarting a combined hormonal contraceptive
following a break of 4
or more weeks
•
Please be alert and see your doctor if you think you may have symptoms
of a blood clot (see
section 2 “Blood clots”)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-Keep this leaflet. You may need to read it again.
-If you have any further questions or need more advice, ask your
doctor, family planning nurse, or
pharmacist.
-This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them.
-If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this lealfet. See section 4. WHAT IS IN THIS LEAFLET
1.
What Nhytideta is and what it is used for
2. What you need to know before you take Nhytideta
3. How to take Nhytideta
4. Possible side effects
5. How to store Nhytideta
6. Contents of the pack and other information
1.
WHAT NHYTIDETA IS AND WHAT IT IS USED FOR
• Nhytideta is a contraceptive tablet and is used to prevent
pregnancy.
• Each tablet contains a small amount of two different female
hormones, namely ethinylestradiol
and gestodene.
• Contraceptive tablets as Nhytideta that contain two hormones are
called “combination”
contraceptives.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE NHYTIDETA
LF-GSTDEE-NL-NL.H.2961.001.IA.019&II.013-D0
3
GENERAL NOTES
Before you start using Nhytideta you should read the information on
blood clots in section 2. It is
particularly important to read the symptoms of a blo
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                SPC-GSTDEE-NL-NL.H.2961.001.A.019
&II.013
-D0
1
SUMMARY OF PRODUCT CHARACTERISTICS
SPC-GSTDEE-NL-NL.H.2961.001.IA.019&II.013-D0
2
1.
NAME OF THE MEDICINAL PRODUCT NHYTIDETA 0,075 MG/ 0,020 MG TABLETTEN
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each white tablet contains 0,075 mg gestodene and 0,020 mg
ethinylestradiol
Excipients with known effect:
Each tablet contains 59.12 mg lactose monohydrate.
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Tablets.
Round, white tablets, with a diameter of 5.7 mm approximately. The
white tablet is debossed with a
‘
_C’_
on one side and ‘
_34’_
on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Oral contraception.
The decision to prescribe Nhytideta should take into consideration the
individual woman’s current
risk factors, particularly those for venous thromboembolism (VTE), and
how the risk of VTE with
Nhytideta compares with other CHCs (see sections 4.3 and 4.4).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Route of administration: oral use
_How to take Nhytideta _
The tablets must be taken every day at approximately the same time, if
necessary with a little liquid,
in the order indicated on the blister pack. One tablet per day should
be taken for 21 days. Each
subsequent pack should be started after a 7-day tablet-free interval
during which time a withdrawal
bleeding will occur. This bleeding usually starts on the 2
nd
or 3
rd
day after taking the last tablet, and
may not stop until the next pack is started.
_How to start taking Nhytideta _
_If no preceding hormonal contraceptive use in the past month _
Taking of the tablets should begin on the first day of the woman’s
natural cycle (i.e. on the first day
of the woman’s menstrual bleeding). One may begin taking the pills
on day 2-5, but in these cases,
it is recommended that a barrier method also be used for the first 7
days on which pills are taken
during the first cycle.
_Changing from a combined hormonal contraceptive (combined oral
contraceptive (COC), vaginal _

                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill enska 03-08-2016
Vara einkenni Vara einkenni enska 03-08-2016